Caris Life Sciences, Inc. - Common Stock (CAI)
Healthcare › Services-Medical Laboratories
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- P/B of 8.72 — trading above book value
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -25.4%
- Revenue growing at 97% annually
Caris Life Sciences, Inc. - Common Stock (CAI) is a Healthcare company operating in Services-Medical Laboratories, listed on the NASDAQ , with a market capitalisation of $5.2 billion . Key value metrics: P/B ratio 8.72, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Caris Life Sciences, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, CAI shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -25.4% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.64.
StockPik's composite Value Score for CAI is 37/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CAI shows revenue growing at 97% year-over-year, with earnings growing at 76%.